Ovarian cancer recurrent

15 trials 7 recruiting MedDRA PT
15 Registered trials
7 Recruiting
12 Unique sponsors
24 Unique IMPs
10 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 10
— ATC code not specified 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
PARP inhibitor 4 substances
Monoclonal antibody (tumor, humanized) 3 substances
Checkpoint inhibitor (PD-1) 2 substances
Kinase inhibitor 2 substances
Platinum compound 1 substance
Anthracycline 1 substance
Antimetabolite 1 substance
Taxane 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (rat) 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 3 Phase II: 6 Phase III/IV: 1 Phase IV: 1 Phase I (Other): 1 Phase I (First in Human): 3

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

3 trials
  • F. Hoffmann-La Roche AG Commercial
    PERTUZUMAB; TRASTUZUMAB
    2023-505102-42-00 3 countries 2014 n=23
    Ended
  • Merck Sharp & Dohme LLC Commercial
    SACITUZUMAB TIRUMOTECAN
    2023-508015-23-00 14 countries 2025 n=251
    Recruiting
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    OLAPARIB
    2024-516842-21-00 1 country 2025 n=200
    Recruiting

Phase II

6 trials
  • AGO Research GmbH Commercial
    CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL; GEMCITABINE HYDROCHLORIDE; NIRAPARIB TOSILATE MONOHYDRATE; OLAPARIB; PACLITAXEL; RUCAPARIB
    2024-516959-40-00 1 country 2021 n=136
    Ended
  • USWM Ct LLC Commercial
    AUTOLOGOUS T CELLS EXPRESSING CD8A AND A T-CELL RECEPTOR TARGETING MAGE-A4; NIVOLUMAB
    2024-512138-13-00 2 countries 2023 n=28
    Ended
  • Verastem Inc. Commercial
    AVUTOMETINIB; DEFACTINIB
    2024-516986-35-00 4 countries 2021 n=75
    Ended
  • Asso De Recherche Cancers Gynecologiques Academic
    MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200; PEMBROLIZUMAB
    2024-516096-32-00 3 countries 2021 n=180
    Ended
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    OLAPARIB
    2024-516841-38-00 1 country 2025 n=100
    Recruiting
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    PEMBROLIZUMAB
    2023-508155-40-00 1 country 2022 n=33
    Ended

Phase III/IV

1 trial
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-506177-35-00 10 countries 2021 n=209
    Ended

Phase IV

1 trial
  • Rita Fior Academic
    IMP not specified
    2023-509598-22-01 1 country 2025 n=276
    Recruiting

Phase I (Other)

1 trial
  • K-Group Beta Inc. Commercial
    AZENOSERTIB; NIRAPARIB
    2024-515196-35-00 1 country 2022 n=150
    Ended

Phase I (First in Human)

3 trials
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB, FIANLIMAB; REGN5668; SARILUMAB; UBAMATAMAB
    2022-501904-83-00 3 countries 2023 n=208
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; SARILUMAB; UBAMATAMAB
    2024-510783-23-00 5 countries 2020 n=237
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 2 Phase III/IV, Phase III 1
Regeneron Pharmaceuticals Inc. Commercial 2 Phase I (First in Human) 2
IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic 2 Phase II, Phase III 2
K-Group Beta Inc. Commercial 1 Phase I (Other) 0
AGO Research GmbH Commercial 1 Phase II 0
USWM Ct LLC Commercial 1 Phase II 0
Verastem Inc. Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Asso De Recherche Cancers Gynecologiques Academic 1 Phase II 0
Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic 1 Phase II 0
Rita Fior Academic 1 Phase IV 1
New trials by year
2020
1
2021
4
2022
2
2023
2
2025
5
← All indication landscapes